Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
Cellectar Biosciences (NASDAQ: CLRB) announced the acceptance of an abstract for poster presentation at the AACR Special Conference on Pancreatic Cancer Research in Boston from September 28-October 1, 2025. The presentation will showcase preclinical data for CLR 121225, the company's novel actinium-based radio conjugate alpha-emitter designed to treat hypoxic pancreatic ductal adenocarcinoma.
Chief Operating Officer Jarrod Longcor will present the poster titled "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225" on September 30. The company reports that preclinical studies have demonstrated promising activity, biodistribution, and uptake across multiple solid tumor animal models, with IND-enabling activities currently in progress.
Cellectar Biosciences (NASDAQ: CLRB) ha annunciato l'accettazione di un abstract per una presentazione poster al AACR Special Conference on Pancreatic Cancer Research che si terrà a Boston dal 28 settembre al 1° ottobre 2025. La presentazione illustrerà i dati preclinici di CLR 121225, il nuovo radio-coniugato a base di actinio dell'azienda, un emettitore alfa progettato per trattare l'adenocarcinoma duttale pancreatico in condizioni di ipossia.
Il Chief Operating Officer Jarrod Longcor presenterà il poster intitolato "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225" il 30 settembre. L'azienda riferisce che gli studi preclinici hanno mostrato attività promettente, distribuzione tissutale e captazione in diversi modelli animali di tumori solidi, e che sono in corso le attività per l'abilitazione all'IND.
Cellectar Biosciences (NASDAQ: CLRB) anunció la aceptación de un resumen para presentación en póster en la AACR Special Conference on Pancreatic Cancer Research en Boston, del 28 de septiembre al 1 de octubre de 2025. La presentación mostrará datos preclínicos de CLR 121225, el nuevo radio-conjugado basado en actinio de la compañía, un emisor alfa diseñado para tratar el adenocarcinoma ductal pancreático hipóxico.
El Director de Operaciones Jarrod Longcor presentará el póster titulado "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225" el 30 de septiembre. La compañía informa que los estudios preclínicos han mostrado actividad prometedora, biodistribución y captación en varios modelos animales de tumores sólidos, y que actualmente se están realizando las actividades para habilitar el IND.
Cellectar Biosciences (NASDAQ: CLRB)는 2025년 9월 28일~10월 1일 보스턴에서 열리는 AACR Special Conference on Pancreatic Cancer Research에 포스터 초록이 채택됐다고 발표했습니다. 이번 발표에서는 저산소성 췌장관선암 치료를 위해 설계된 회사의 신규 악티늄 기반 방사선 접합체 CLR 121225에 대한 전임상 데이터를 소개합니다.
최고운영책임자(COO) Jarrod Longcor가 9월 30일 "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225"라는 제목의 포스터를 발표할 예정입니다. 회사는 전임상 연구에서 다수의 고형종양 동물 모델에서 유망한 효능, 생체분포 및 섭취를 보였으며 IND 승인 준비 관련 활동이 진행 중이라고 전했습니다.
Cellectar Biosciences (NASDAQ: CLRB) a annoncé l'acceptation d'un résumé pour une communication par poster à la AACR Special Conference on Pancreatic Cancer Research à Boston du 28 septembre au 1er octobre 2025. La présentation mettra en avant des données précliniques pour CLR 121225, le nouveau conjugué radiothérapeutique à base d'actinium de la société, émetteur alpha conçu pour traiter l'adénocarcinome canalaire pancréatique en conditions hypoxiques.
Le directeur des opérations Jarrod Longcor présentera le poster intitulé "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225" le 30 septembre. La société indique que les études précliniques ont montré une activité prometteuse, une biodistribution et une captation dans plusieurs modèles animaux de tumeurs solides, et que les activités visant à permettre le dépôt d'un IND sont en cours.
Cellectar Biosciences (NASDAQ: CLRB) gab bekannt, dass ein Abstract für eine Posterpräsentation auf der AACR Special Conference on Pancreatic Cancer Research in Boston vom 28. September bis 1. Oktober 2025 akzeptiert wurde. Die Präsentation wird präklinische Daten zu CLR 121225 vorstellen, dem neuartigen actinium-basierten Radiokonjugat des Unternehmens, einem Alpha-Emitter zur Behandlung hypoxischer Pankreasduktaladenokarzinome.
Chief Operating Officer Jarrod Longcor wird das Poster mit dem Titel "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225" am 30. September vorstellen. Das Unternehmen berichtet, dass präklinische Studien vielversprechende Wirksamkeit, Biodistribution und Aufnahme in mehreren Tiermodellen solider Tumoren gezeigt haben und IND-fähig machende Aktivitäten derzeit im Gange sind.
- None.
- None.
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts. The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.
“We are excited to present our poster at the AACR Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors,” said Jarrod Longcor, chief operating officer of Cellectar. “We are encouraged that preclinical studies to date have demonstrated excellent activity, biodistribution and uptake of CLR 225 across multiple solid tumor animal models and are currently advancing IND-enabling activities.”
Details of the poster presentation are as follows:
| Title: | “Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate” |
| Poster: | B032 |
| Date/Time: | Tuesday, September 30, 6-9 p.m. Presenter: Jarrod Longcor |
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes its lead assets: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope); CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Forward Looking Statements Disclaimer
This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarterly period ending June 30, 2025. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
INVESTORS:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When is Cellectar Biosciences (CLRB) presenting at the AACR Special Conference on Pancreatic Cancer Research?
What will Cellectar Biosciences (CLRB) present at the AACR conference?
Who will present Cellectar's (CLRB) poster at the AACR Special Conference?
What are the initial results of CLR 121225 in preclinical studies?
